510(k) K260235
K260235 is an FDA 510(k) premarket notification submitted by Datar Cancer Genetics Private Limited for the device "CellDx-Tissue". The FDA issued a decision of Substantially Equivalent on May 12, 2026. The device falls under product code PZM (Next Generation Sequencing Based Tumor Profiling Test), a Class II device regulated under 21 CFR 866.6080.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- May 12, 2026
- Date Received
- January 26, 2026
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- Yes
Device Classification
- Device Name
- Next Generation Sequencing Based Tumor Profiling Test
- Device Class
- Class II
- Regulation Number
- 866.6080
- Review Panel
- PA
- Submission Type
A next-generation sequencing based tumor profiling test is a qualitative in vitro diagnostic test intended to detect mutations in a broad panel of targeted genes that are somatically altered in malignant neoplasms from tumor specimens obtained from patients diagnosed with malignant solid neoplasms using targeted next-generation sequencing.